Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Nachrichtenquelle: globenewswire
19.10.2020, 14:00  |  267   |   |   

Aequus Announces Approval of Third Revenue Generating Product

VANCOUVER, British Columbia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today that together with its partner, Medicom Healthcare Ltd. (“Medicom”), has been issued a new Medical Device License for the first of three product submissions made for the EvolveTM preservative free dry eye product line. The new Medical Device License has been issued for EvolveTM Intensive Gel – a unique cross linked combination of Carbomer 980, Hyaluronate and glycerol – which act together to provide intensive, durable hydration for patients with moderate to severe forms of Dry Eye Disease. The formulation will be made available in an easy-squeeze eye drop bottle, containing 360 drops, and no preservatives, phosphates or buffers.

“Evolve Intensive Gel is a one-of-a-kind formulation in Canada, and is only the first of a full line of Eye Care Professional Exclusive products being launched by Aequus, that will not only improve treatment and compliance for better patient outcomes, but create an improved revenue stream for Eye Care professionals who spend additional time and resources treating dry eye patients in practice,” said Grant Larsen, Chief Commercial Officer at Aequus.

“We are delighted that our partner Aequus Pharmaceuticals has achieved approval of Evolve Intensive Gel by Health Canada. We know that long term use of preservatives will damage the cornea and the Evolve preservative free dry eye product line can help with the symptoms of dry eye whilst protecting the cornea from that damage,” said Simon Martin, founder and CEO of Medicom Healthcare. “Called Revive in other countries, this product is a revolutionary triple action matrix gel designed for lubrication, restoration & protection of the ocular surface, providing extended ocular residency time.”

“This approval marks an important step for Aequus,” said Aequus CEO Doug Janzen. “The Evolve line of products are going to be important revenue drivers for Aequus and we are pleased that Evolve Intensive Gel was the first approved. Launch activities for all three Evolve products are underway while the remaining two EvolveTM products are currently under review for approval with Health Canada.”

ABOUT DRY EYE DISEASE

Dry eye disease (DED) is a common disorder of the tear film that leads to ocular surface damage over time. Previous research has shown DED reduces health and vision related quality of life and that it carries a considerable economic burden of disease. DED affects approximately 6.3 million Canadians, representing approximately 21% of the population.1 Home confinement, e-learning and working from home due to the COVID-19 pandemic means spending more time looking at screens, which has a significant impact on eye health. A combination of reduced frequency and intensity of blinking during screen time increases the risk of inducing or exacerbating dry eye disease.2

Seite 1 von 3
Aequus Pharmaceuticals Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada Aequus Announces Approval of Third Revenue Generating ProductVANCOUVER, British Columbia, Oct. 19, 2020 (GLOBE NEWSWIRE) - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel